BRAF V600E mutation

From Aaushi
Jump to navigation Jump to search

Indications

Clinical significance

Procedure

More general terms

Additional terms

References

  1. FDA NEWS RELEASE: Aug. 17, 2011 FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer
  2. FDA News Release: May 29, 2013 FDA approves two drugs, companion diagnostic test for advanced skin cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199
  3. 3.0 3.1 Margonis GA, Buettner S, Andreatos N et al Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surg. Published online May 16, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29799910 https://jamanetwork.com/journals/jamasurgery/fullarticle/2680564
  4. 4.0 4.1 Planchard D, Smit EF, Groen HJM et al Dabrafenib plus trametinib in patients with previously untreated BRAF-V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28919011